Matches in Wikidata for { <http://www.wikidata.org/entity/Q64393457> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- Q64393457 description "clinical trial" @default.
- Q64393457 description "ensayu clínicu" @default.
- Q64393457 description "klinisch onderzoek" @default.
- Q64393457 description "клінічне випробування" @default.
- Q64393457 name "Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis" @default.
- Q64393457 type Item @default.
- Q64393457 label "Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis" @default.
- Q64393457 prefLabel "Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis" @default.
- Q64393457 P1050 Q64393457-EB76C092-5646-48AE-B02D-5EC7C4AD1604 @default.
- Q64393457 P1132 Q64393457-E470BF34-F70C-4AA0-A20B-CB96A0635ADD @default.
- Q64393457 P1476 Q64393457-DCE138FF-1AB6-4988-89E7-767FC2263AAA @default.
- Q64393457 P17 Q64393457-140BC820-D90C-4FAE-BB4C-C1B52BCFAF89 @default.
- Q64393457 P17 Q64393457-188924CF-F92A-41DB-9FE9-A6C7C3D40393 @default.
- Q64393457 P17 Q64393457-221E704A-12C4-4208-B84C-C66BF09AAE8B @default.
- Q64393457 P17 Q64393457-27A64F01-F3C7-44A3-A01A-7526BCC62C6F @default.
- Q64393457 P17 Q64393457-2D52E492-680F-4DCD-A969-3C28C3594619 @default.
- Q64393457 P17 Q64393457-32EA878B-7E52-4208-850A-B9014DF1AFFA @default.
- Q64393457 P17 Q64393457-35400724-C719-441D-A7E5-06605391A33B @default.
- Q64393457 P17 Q64393457-38B82161-3FE7-4B82-87F5-9CC96C5254B3 @default.
- Q64393457 P17 Q64393457-3B40EF42-3B3B-4F4A-B762-36CC97B09B81 @default.
- Q64393457 P17 Q64393457-3EAFFB69-B9D4-422D-86BE-4DBE4C6FDE4B @default.
- Q64393457 P17 Q64393457-6A9B55CE-FA10-4441-BBD2-D5CC581B045E @default.
- Q64393457 P17 Q64393457-6DB9608A-6892-4529-9229-C7CBE74CC3FD @default.
- Q64393457 P17 Q64393457-7463102F-10C3-4F08-9A7C-F6A704D7E917 @default.
- Q64393457 P17 Q64393457-769E4A1A-F925-4597-B116-E742AD73ABEF @default.
- Q64393457 P17 Q64393457-791C5971-64A9-4F8D-9684-FD42A2D34388 @default.
- Q64393457 P17 Q64393457-806940A0-230C-4048-A3F4-DB578870F7BB @default.
- Q64393457 P17 Q64393457-819D9CCB-12BB-4164-B3B2-E4ABEDF927FF @default.
- Q64393457 P17 Q64393457-862ABF83-847D-4D03-9B0D-F2BEEACB6328 @default.
- Q64393457 P17 Q64393457-96F04020-7031-4B22-B36F-E6D8BBB55251 @default.
- Q64393457 P17 Q64393457-A26DB745-E30C-4967-8FC7-8C468E4A700E @default.
- Q64393457 P17 Q64393457-BF3946CC-98EB-4FB3-8263-C126B7F29E79 @default.
- Q64393457 P17 Q64393457-C2B066F0-D140-47A5-A0F7-6E4610F93013 @default.
- Q64393457 P17 Q64393457-CAEB4CD8-7146-4212-8415-5FEB0BECCB43 @default.
- Q64393457 P17 Q64393457-D2397674-7D9C-4B09-A035-D0456ACD3061 @default.
- Q64393457 P17 Q64393457-E23F59EE-887C-42E9-B05A-2B53F7849F02 @default.
- Q64393457 P17 Q64393457-E7EB567C-8FF0-4DE0-B53E-BDEAD81349B6 @default.
- Q64393457 P1813 Q64393457-F1328CE5-F4B4-41B8-95D3-16C07E6850A8 @default.
- Q64393457 P2899 Q64393457-4116A9BA-11B6-441B-AA90-094B0D504B76 @default.
- Q64393457 P3098 Q64393457-5EDBE422-37DE-4F63-9D4C-E7204D833085 @default.
- Q64393457 P31 Q64393457-7D100AF6-E49E-45A7-BEDA-768F73E16B64 @default.
- Q64393457 P580 Q64393457-19A18636-BB09-4D7D-B872-8C840A8611FE @default.
- Q64393457 P582 Q64393457-7ECB3EEA-3FAF-42B5-A801-38DA79D4A347 @default.
- Q64393457 P6099 Q64393457-4ACBD789-2DAA-4725-A7C3-A453235C425C @default.
- Q64393457 P6153 Q64393457-06DDAEA5-575C-470E-AEB6-3FA64F6EFA81 @default.
- Q64393457 P8363 Q64393457-81034158-6968-47D6-9870-43637CF59BD3 @default.
- Q64393457 P859 Q64393457-BDE51113-0A02-418A-8077-79844C571F44 @default.
- Q64393457 P1050 Q170990 @default.
- Q64393457 P1132 "+998" @default.
- Q64393457 P1476 "A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5)" @default.
- Q64393457 P17 Q145 @default.
- Q64393457 P17 Q16 @default.
- Q64393457 P17 Q183 @default.
- Q64393457 P17 Q191 @default.
- Q64393457 P17 Q211 @default.
- Q64393457 P17 Q27 @default.
- Q64393457 P17 Q28 @default.
- Q64393457 P17 Q29 @default.
- Q64393457 P17 Q298 @default.
- Q64393457 P17 Q30 @default.
- Q64393457 P17 Q33 @default.
- Q64393457 P17 Q34 @default.
- Q64393457 P17 Q35 @default.
- Q64393457 P17 Q37 @default.
- Q64393457 P17 Q38 @default.
- Q64393457 P17 Q40 @default.
- Q64393457 P17 Q41 @default.
- Q64393457 P17 Q414 @default.
- Q64393457 P17 Q55 @default.
- Q64393457 P17 Q668 @default.
- Q64393457 P17 Q774 @default.
- Q64393457 P17 Q801 @default.
- Q64393457 P17 Q869 @default.
- Q64393457 P17 Q881 @default.
- Q64393457 P17 Q928 @default.
- Q64393457 P17 Q96 @default.
- Q64393457 P1813 "FUTURE5" @default.
- Q64393457 P2899 "+18" @default.
- Q64393457 P3098 "NCT02404350" @default.
- Q64393457 P31 Q30612 @default.
- Q64393457 P580 "2015-08-31T00:00:00Z" @default.
- Q64393457 P582 "2017-08-16T00:00:00Z" @default.
- Q64393457 P6099 Q42824827 @default.
- Q64393457 P6153 Q507154 @default.
- Q64393457 P8363 Q78089383 @default.
- Q64393457 P859 Q507154 @default.